Japanese cosmetics maker selling skincare and beauty products primarily through a direct-sales/door-to-door model.
Japanese cosmetics maker selling skincare and beauty products primarily through a direct-sales/door-to-door model.
Sells through consultants who counsel customers in person, so the company controls pricing and skips retailer margins, and sales depend on repeat customers who stay with their consultant. Skin care is the core and health foods a side line. Japan carries the business.
In one line: Japan's Avon/Mary Kay for direct-sales cosmetics.
Moat: narrow (brand, distribution). Established direct-sales consultant network for skincare in Japan.
Headquarters: Kobe, Japan · Founded: 1954
Size Noevir (4928.T) is a Japan Consumer Staples company (Household/Personal Care) with a market value of $978M, the 747th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥4,565 on 18 Nov 2026.
Performance Over six months the shares gained 6.7%, against +5.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 3.2% over the last twelve months (peer median +10.2%); the operating margin is 27.8% (peer median 8.6%).
Valuation It trades at 20.4× forward earnings against a peer median of 18.7× (9th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 35.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 9 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥62.7B | ¥62.7B | ¥64.7B | ¥63.8B | ¥62.6B |
| Revenue growth | — | -3% | +1% | +2% | — |
| Gross profit | ¥42.3B | ¥42.3B | ¥43.3B | ¥43.2B | ¥42.6B |
| EBITDA | ¥18.5B | ¥10.5B | ¥11.9B | ¥12.4B | ¥12.2B |
| Net income | ¥8.22B | ¥8.22B | ¥8.03B | ¥7.97B | ¥7.67B |
| Free cash flow | n/a | ¥3.93B | ¥5.66B | ¥8.50B | ¥6.89B |
| Capital expenditure | n/a | ¥859M | ¥2.52B | ¥1.01B | ¥1.05B |
| Total debt | ¥664M | ¥664M | ¥742M | ¥828M | ¥914M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Noevir 4928.T | $978M | +7% | -3% | 28% | 20.4× | -12.8% |
| Pola Orbis 4927.T | $2.04B | +15% | +1% | 11% | 30.6× | -2.0% |
| KOSE 4922.T | $2.16B | +16% | +4% | 5% | 29.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4928.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.7% | -2.5% | 11th highest of 21 |
| 6-month return | +6.7% | +5.6% | 11th highest of 21 |
| Distance from 52-week high | -10.0% | -33.1% | 4th highest of 21 |
| Revenue growth (TTM) | -3.2% | +10.2% | 4th lowest of 21 |
| Operating margin | 27.8% | 8.6% | highest of 21 |
| Forward P/E | 20.4× | 18.7× | 9th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | -12.8% | 4.4% | least demanding of 18 |
| Growth delivered (Del g) | +4.1% | +10.8% | 5th lowest of 18 |
| Hurdle (Req g minus delivered) | -16.9 pp | -4.4 pp | 5th least demanding of 18 |
| ROIC minus cost of capital | +35.2 pp | +4.7 pp | 3rd highest of 21 |
| EV / EBITDA | 7.1× | 10.3× | 2nd cheapest of 11 |
| Net debt / EBITDA | -1.4× | -0.9× | 4th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Noevir 4928.T | Japan | $978M | +7% | -3% | 28% | 20.4× | -12.8% | +4.1% |
| Tongling Jieya Biologic Technology 301108.SZ | China | $933M | +56% | +24% | 5% | 52.5× | 28.5% | +0.8% |
| Shanghai Forest Cabin Cosmetics 2657.HK | Hong Kong | $1.04B | +15% | +74% | 18% | 11.8× | 11.3% | +49.0% |
| Runben Biotechnology 603193.SS | China | $918M | -30% | +13% | 21% | 18.5× | 1.5% | +28.4% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $912M | +13% | +10% | 11% | 27.9× | 3.7% | +10.8% |
| Cosmecca Korea 241710.KS | South Korea | $847M | +23% | +42% | 12% | 16.3× | n/a | n/a |
| Galaxy Surfactants GALAXYSURF.NS | India | $845M | +22% | +30% | 9% | 17.6× | 18.5% | +13.7% |
| d'Alba Global 483650.KS | South Korea | $1.13B | -55% | +49% | 22% | 12.0× | -6.6% | +53.0% |
| SYoung 300740.SZ | China | $816M | -48% | +14% | 3% | 33.4× | 14.0% | +6.1% |
| Shanghai Chicmax Cosmetics 2145.HK | Hong Kong | $1.17B | -42% | +23% | 8% | 14.4× | -6.1% | +21.2% |
| Jyothy Labs JYOTHYLAB.NS | India | $762M | -9% | +5% | 8% | 40.8× | 34.5% | +8.9% |
| Milbon 4919.T | Japan | $743M | +48% | +8% | 14% | 25.7× | -3.3% | +8.2% |
| Edgewell Personal Care EPC | United States | $1.30B | +67% | -10% | 7% | 14.2× | n/a | n/a |
| Hangzhou Haoyue Personal Care 605009.SS | China | $726M | -18% | +10% | 6% | 17.7× | 4.4% | +7.7% |
| Chongqing Baiya Sanitary Products 003006.SZ | China | $1.35B | +27% | 0% | 3% | 37.3× | 28.8% | +22.8% |
| Intercos ICOS.MI | Italy | $1.43B | +12% | -5% | 9% | 18.9× | 4.3% | +11.5% |
| Harbin Fuerjia Technology 301371.SZ | China | $1.51B | -39% | +28% | 20% | 21.4× | 7.5% | +3.6% |
| AMOREPACIFIC 002790.KS | South Korea | $1.61B | +2% | +9% | 9% | 8.5× | -5.7% | -1.3% |
| Shanghai Jahwa United 600315.SS | China | $1.61B | -15% | +9% | 2% | 15.4× | 15.3% | -2.1% |
| Guangdong Marubi Biotechnology 603983.SS | China | $1.62B | +9% | -6% | 2% | 45.5× | n/a | n/a |
| Yunnan Botanee Bio-Technology 300957.SZ | China | $1.69B | -33% | +7% | 9% | 19.1× | 2.6% | +15.3% |